<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/66CB5717-9D16-439F-8700-FCC05E0EB599"><gtr:id>66CB5717-9D16-439F-8700-FCC05E0EB599</gtr:id><gtr:name>Biolauncher Limited</gtr:name><gtr:address><gtr:line1>UNIT 20B BOURTON INDUSTRIAL PARK , BOURTON ON THE WATER</gtr:line1><gtr:city>CHELTENHAM</gtr:city><gtr:postCode>GL54 2HQ</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/66CB5717-9D16-439F-8700-FCC05E0EB599" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>66CB5717-9D16-439F-8700-FCC05E0EB599</gtr:id><gtr:name>Biolauncher Limited</gtr:name><gtr:address><gtr:line1>UNIT 20B BOURTON INDUSTRIAL PARK , BOURTON ON THE WATER</gtr:line1><gtr:city>CHELTENHAM</gtr:city><gtr:postCode>GL54 2HQ</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>45961.0</gtr:offerGrant><gtr:projectCost>93283.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/96A3346A-CD41-47D4-B603-3F2F273588C5" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>96A3346A-CD41-47D4-B603-3F2F273588C5</gtr:id><gtr:name>Isogenica Limited</gtr:name><gtr:address><gtr:line1>THE MANSION CHESTERFORD RESEARCH PARK , LITTLE CHESTERFORD</gtr:line1><gtr:city>SAFFRON WALDEN</gtr:city><gtr:postCode>CB10 1XL</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>274607.0</gtr:offerGrant><gtr:projectCost>560422.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5655D9DF-B87F-409E-9BD2-8CE1BDC910C3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>5655D9DF-B87F-409E-9BD2-8CE1BDC910C3</gtr:id><gtr:name>Cresset Biomolecular Discovery Limited</gtr:name><gtr:address><gtr:line1>Biopark Hertfordshire
Broadwater Road</gtr:line1><gtr:city>Welwyn Garden City</gtr:city><gtr:postCode>AL7 3AX</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>179345.0</gtr:offerGrant><gtr:projectCost>361802.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A232E354-7155-42BE-94EA-947529415055"><gtr:id>A232E354-7155-42BE-94EA-947529415055</gtr:id><gtr:firstName>Grants</gtr:firstName><gtr:surname>Team</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=101232"><gtr:id>C04B77D0-BBB1-4BF7-9DDA-BC3DA30C5DBA</gtr:id><gtr:title>Demonstrating an innovative End-to-End Drug Discovery (E2D2) platform</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>101232</gtr:grantReference><gtr:abstractText>The E2D2 project will develop and demonstrate novel technologies combined in an integrated approach that identifies active medicinal drugs by exploiting Omics information. By developing technologies to link together the platforms of three UK SMEs, E2D2 will enable an information-led platform approach for drug discovery, delivering novel active drug compounds significantly faster and more cost-effectively than is currently possible. In addition, the approach will deliver candidate drugs that incorporate greater levels of innovation and patentability than is currently achieved. This will have a dramatic impact on our ability to exploit investments in genomic data generation technology, advances in large scale proteomics and new bioinformatics approaches to extract commercial value and deliver benefits to patients.</gtr:abstractText><gtr:fund><gtr:end>2014-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2012-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>499913</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">101232</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>